Martin Johnson joins Zoan Biomed to lead development of its 3D Printing proposition

by Stephen

Feb 12

Martin leads the development of Zoan’s portfolio of 3D printable materials and medical devices in partnership with industry incumbents and research centres. He brings deep R&D experience with his work with WWF and the Dutch Environment Ministry building on 15+ years’ experience in marine biogeochemisty research at the University of East Anglia. Other areas of expertise include: carbon storage in marine ecosystems and control of biogeochemicals in aquaculture systems. Martin has a PhD in Marine Biogeochemistry and a Degree in Environmental Science.

Latest News

Visiting Cellink

Thank you to the Cellink team for hosting us in their highly impressive facility in Gothenberg.

We are making excellent progress towards our development of 3D bioprinted tissue model containing sustainably grown coral skeletal particles.

4 days ago

Zoan and partners at TERMIS 2023

Zoan, Cellink and University of Galway collaboration on 3D printable coral-containing bioinks to present results at TERMIS, Manchester, 28-31st March 2023: Biocompatibility of 3D bioprinted tissue model prototypes containing sustainably grown coral skeletal particles for orthopedic applicationsE. Pernevik et. al. Zoan and partners at CELLINK and University of Galway will be presenting the early results from our coral bioink…

2 months ago

Our Sustainability Model

As a Med Tech company that aims to improve people’s health, we recognise the need to preserve a healthy environment. The link between human and environmental health is well established: the WHO states that one in four premature deaths is related to environmental issues caused by humans and the World Bank acknowledges that sustainable management…

3 months ago

Novel Collaboration between Zoan Biomed and University of Galway to Assess Laboratory Bone Formation

Zoan Biomed and the University of Galway to develop high throughput rapid assessment methods for biocompatibility and osteogenic potential of orthopaedic scaffold; reducing time to clinical data and developing a path to remove the need for animal testing.

5 months ago

Contact Us

To find out more about Zoan BioMed get in touch